4.11.2013

Read this issue and previous issues online.

Follow us on:
Follow us on Twitter  Follow us on Facebook  Follow us on Flickr Follow us on YouTube   Follow us on LinkedIn

Announcements / Press Releases

RBM launches communication campaign to track progress to 2015 [RBM] — (English)
The Roll Back Malaria (RBM) Partnership is launching a new campaign to track country progress and actions to meet 2015 targets. Drawing on the three year World Malaria Day theme "Invest in the future: Defeat malaria", the communication campaign will highlight and benchmark three critical milestones in 2013, 2014 and 2015, providing a window on political commitment, shared investments and the application of technical and scientific know-how in tackling the disease in priority and high burden countries. ...

Roll Back Malaria Partnership – Development of a Second Generation GMAP [RBM] — (English)
RBM Partnership is seeking proposals from suitably qualified organisations and consortiums to under work in developing the next generation of the Global Malaria Action Plan (GMAP). Proposals must be received no later than Monday 25 November 2013, 12:00 hours, Geneva time to be considered...

Bayer CropScience and IVCC offer new tool for malaria control [Bayer CropScience and IVCC] — (English)
The World Health Organization Pesticide Evaluation Scheme (WHOPES) has issued a recommendation for a new polymer-enhanced, long-lasting Indoor Residual Spray for malaria vector control. This deltamethrin based spray was jointly developed by Bayer CropScience and IVCC (the Innovative Vector Control Consortium). It represents a viable cost-effective alternative to DDT for malaria control programs. Market introduction across Sub-Saharan Africa and other malaria endemic areas is expected to occur during 2014 once relevant national regulatory approvals are in place...

Malaria control to elimination - emerging consensus on 'accelerating to zero' [ACT Consortium] — (English)
The Director of the ACT Consortium talks about the concept of malaria eradication on The Lancet Global Health Blog after attending the 6th Pan-African Multilateral Initiative on Malaria conference (MIM) in Durban, South Africa...

GlaxoSmithKline and AMREF Celebrate 25 Years of a Vibrant, Dynamic and Robust Partnership [AMREF] — (English)
On October 29, 2013, AMREF and GSK celebrated a long time partnership spanning over 25 years of working together to create lasting health change in Africa, positively impacting the lives of over 3 million people...

Community engagement is key to malaria prevention [AIRS] — (English)
Communications campaigns are critical to malaria prevention. For indoor residual spraying to be effective at preventing malaria at least 80% of households must allow their homes to be sprayed, according to the World Health Organization. Learn how AIRS is using community meetings, radio, well-child visits and door-to-door canvassing to encourage participation in these malaria prevention campaigns...

Jeremy Lefroy MP encourages more Parliaments to set up special interest groups on Malaria and Neglected Tropical Diseases [APPMG] — (English)
Whilst in Washington DC for the annual conference of the Parliamentary Network on the World Bank and IMF, Jeremy Lefroy MP, Chair of the All Party Parliamentary Group (APPG) on Malaria and Neglected Tropical Diseases (NTDs) met with the co-chair of the US Senate working group on Malaria and NTDs- Senator Roger Wicker along with the Global Network’s Neeraj Mistry and Mr. Ibrahim Souleymane MP from the National Assembly of Niger...

Bestnet A/S Adds DuraNet® to Their Product Portfolio [Bestnet Europe press releaase] — (English)
Bestnet A/S announced today that the company has entered into an agreement with Shobikaa Impex Pvt Ltd. in regard to DuraNet® Long Lasting Insecticide Nets (LLINs). On October 27, 2013 Bestnet obtained a license to manufacture DuraNet® at all Bestnet manufacturing facilities worldwide. Further, Bestnet will market, promote, sell and distribute DuraNet® in its own name, and Bestnet will participate in the worldwide tender business with DuraNet®...

The UCSF Global Health Group publishes malaria-eliminating country briefings [GHS] — (English)
The Global Health Group's Malaria Elimination Initiative documents and disseminates progress and remaining challenges in the 34 malaria-eliminating countries, shedding light on the unprecedented success that has happened across the globe and the additional resources or solutions that will help successful elimination and thus shrink the malaria map. An updated series of briefings on the 34 malaria-eliminating countries is now available...

Funding opportunity: Calls for MESA proposals on Malaria Elimination research [APLMA] — (English)
Researchers are invited to apply for operational research grants from the Malaria Eradication Scientific Alliance (MESA). Up to four grants are available up to 200,000 USD. The expected project period is between 12 –18 months. The deadline for submissions is Wednesday, 11 December 2013...

Tenth PSMWG Meeting Documents online [RBM PSMWG] — (English)
Documents and presentations...

Alliance Malaria Prevention Conference Call Minutes October 16th 2013 [AMP] — (English)
The AMP partnership conducts a weekly conference call on Wednesday at 10:00 EST. All members of the partnership are encouraged to participate in the weekly conference call via a toll free number. The call focuses on monitoring country progress, identifying bottlenecks, organizing technical support at both country level and remote (via e-mail, conference call), and sharing better practice...

RBM Partnership: Deputy Executive Director [RBM] — (English)
Grade: D1
Contract type: Fixed-Term Appointment
Duration of contract: 2 years
Application Deadline: 13 November 2013 ...


Senior Program Officer, Vector Control (Malaria) [BM Gates Foundation] — (English)
The Malaria Program Strategy Team (PST) is recruiting a Senior Program Officer to strategically develop and manage a portfolio of complex investments requiring high-level grant management skills, monitoring, and evaluation...

4.11.2013

{title} [{articlesource}] — ({language})
{description}...

3.13.2013

{title} [{articlesource}] — ({language})
{description}...

2.11.2013

{title} [{articlesource}] — ({language})
{description}...

1.11.2013

{title} [{articlesource}] — ({language})
{description}...

31.10.2013

{title} [{articlesource}] — ({language})
{description}...

30.10.2013

{title} [{articlesource}] — ({language})
{description}...

29.10.2013

{title} [{articlesource}] — ({language})
{description}...

Articles requiring subscription or registration

Malaria vaccine on track [Nature Reviews Drug Discovery 12, 817 (2013) doi:10.1038/nrd4173] — (English)
GlaxoSmithKline (GSK) presented 18-month safety and efficacy data for RTS,S and plans to submit the vaccine for regulatory review next year...

Intervention to Promote Patients' Adherence to Antimalarial Medication: A Systematic Review [Am J Trop Med Hyg 2013 12-0598] — (English)
This study aimed to explore the effectiveness of existing interventions promoting adherence to antimalarial drugs by systematic review...

Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine [Cochrane Database Syst Rev. 2013 Oct 26;10:CD004389. doi: 10.1002/14651858.CD004389.pub3.] — (English)
Compares alternative primaquine regimens to the recommended 14-day regimen for preventing relapses (radical cure) in people with P. vivax malaria treated for blood stage infection with chloroquine. We also summarize trials comparing primaquine to no primaquine that led to the recommendation for the 14-day regimen...

Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria [Cochrane Database Syst Rev. 2013 Oct 25;10:CD008492. doi: 10.1002/14651858.CD008492.pub3] — (English)
Compares artemisinin-based combination therapies (ACTs) with alternative antimalarial regimens for treating acute uncomplicated P. vivax malaria...

Host susceptibility to malaria in human and mice: compatible approaches to identify potential resistant genes [Physiol. Genomics October 29, 2013 physiolgenomics.00044.2013] — (English)
Novel genetic tools including animal model were recently developed and will offer new opportunities for identifying genetic factors underlying host phenotypic response to malaria, which will help in better therapeutic strategies including vaccine and drug development...

The in vitro effects of sulfadoxine/pyrimethamine and artemether/lumefantrine on the viscoelasticity of erythrocyte membrane of healthy females [Clinical Hemorheology and Microcirculation] — (English)
This study investigated the effect of these drugs on the viscoelasticity of erythrocytes of ten healthy female subjects using the BioProfiler. The concentration for each of the two drugs were determined based on the therapeutic dose as normal, half the therapeutic dose as low and double the therapeutic dose as high...

Characteristic Age Distribution of Plasmodium vivax Infections after Malaria Elimination on Aneityum Island [IAI.00931-13] — (English)
By conducting malariometric surveys of the entire population of Aneityum we investigated age distribution of parasites during this epidemic in the context of anti-malaria antibody levels and parasite antigen diversity...

HLA class II (DR0401) molecules induce Foxp3+ Treg suppression of B cells in Py17XNL malaria [IAI.00272-13] — (English)
In order to better understand the correspondence between murine malaria models and human malaria, and in particular the role of MHC (HLA) class II molecules, we studied the ability of humanized mice expressing human HLA class II molecules to clear Py17XNL infection...

Plasmodium vivax Chloroquine Resistance and Anemia in the Western Brazilian Amazon [AAC.02279-12] — (English)
This study estimated in vivo CQ-resistance in uncomplicated patients with P. vivax in use of CQ and primaquine simultaneously, in the Brazilian Amazon...

Potential efficacy of citicoline as adjunct therapy in the treatment of cerebral malaria [AAC.02591-12] — (English)
We evaluated the efficacy of CTC as adjunct therapy to aid the recovery from experimental CM. We show that CTC reduces MP production in vitro, and, in combination with artesunate in vivo, confers partial protection against CM and prolongs survival...